Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214

Maybe I’m a little late. But in december Nektar announced the following:

Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors.  NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells). That’s some very nice news and the stocprice jumped.


the Wiseguy

Stock trader, Owner and Administrator of "". . . "TA is like surfing. You don't have to know a lot about het physics of tides to catch a good wave. You just have to be able to sense when it's happening and have the drive to act at the right time"

Geef een reactie

Deze website gebruikt Akismet om spam te verminderen. Bekijk hoe je reactie-gegevens worden verwerkt.